⌘K
Loading ticker…
As of 2026-08-24, PTC Therapeutics, Inc. (PTCT) has a 3-month relative strength percentile of 55 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 52. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.8%, relative volume 0.73×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
PTCT is in a stage 1 base, week 2. Currently in a 32-day base; basing ADR 3.7% (broad 4.0%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: -8.1% / -3.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
PTCT appears in 1 ETF as of Jun 2026: PSC at 0.47% weight, $11M notional.
Held by 119 ETFs · $1.5B across latest filings · largest weight 3.69% (IBRN).
Top 1 by value, from SEC N-PORT-P filings dated Jun 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| PSC | 0.47% | $11M | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PTCT Jan avg: 3.99% median: 0.54% win: 50% σ: 11.21% n: 4 2022-04-12 → 2026-07-31 | PTCT Feb avg: 3.48% median: 1.61% win: 50% σ: 13.56% n: 4 2022-04-12 → 2026-07-31 | PTCT Mar avg: 1.56% median: 1.55% win: 50% σ: 7.75% n: 4 2022-04-12 → 2026-07-31 | PTCT Apr avg: 0.07% median: -2.20% win: 40% σ: 12.52% n: 5 2022-04-12 → 2026-07-31 | PTCT May avg: -3.36% median: -2.65% win: 40% σ: 17.03% n: 5 2022-04-12 → 2026-07-31 | PTCT Jun avg: 5.70% median: 0.66% win: 60% σ: 19.58% n: 5 2022-04-12 → 2026-07-31 | PTCT Jul avg: 1.73% median: 6.69% win: 60% σ: 11.15% n: 5 2022-04-12 → 2026-07-31 | PTCT Aug avg: 2.90% median: 1.13% win: 50% σ: 8.82% n: 4 2022-04-12 → 2026-07-31 (current) | PTCT Sep avg: -3.33% median: 2.78% win: 75% σ: 28.57% n: 4 2022-04-12 → 2026-07-31 | PTCT Oct avg: -5.52% median: -4.37% win: 50% σ: 17.69% n: 4 2022-04-12 → 2026-07-31 | PTCT Nov avg: 17.07% median: 16.35% win: 100% σ: 8.48% n: 4 2022-04-12 → 2026-07-31 | PTCT Dec avg: 0.73% median: -2.56% win: 50% σ: 14.09% n: 4 2022-04-12 → 2026-07-31 |